As such it is possible that this observation may have potential implications for patient management for checkpoint inhibitors given that CD8 + tumour infiltrating lymphocytes are associated with better outcome in NSCLC [82, 83]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.